BG Medicine Inc (BGMD) financial statements (2020 and earlier)

Company profile

Business Address 880 WINTER STREET
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments24813
Cash and cash equivalents24813
Restricted cash and investments   0
Receivables0000
Inventory, net of allowances, customer advances and progress billings0000
Inventory0000
Prepaid expense 00
Prepaid expense and other current assets1
Other undisclosed current assets0(0)0 
Total current assets:25915
Noncurrent Assets
Property, plant and equipment0000
Intangible assets, net (including goodwill)0000
Intangible assets, net (excluding goodwill)0000
Investments and other noncurrent assets00
Other undisclosed noncurrent assets00  
Total noncurrent assets:0011
TOTAL ASSETS:25915
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1235
Accounts payable1111
Accrued liabilities0124
Employee-related liabilities 001
Interest and dividends payable 0  
Debt 343
Deferred revenue and credits0   
Other liabilities0000
Other undisclosed current liabilities (0)(0)(1)
Total current liabilities:1578
Noncurrent Liabilities
Long-term debt and lease obligation  37
Long-term debt, excluding current maturities  37
Liabilities, other than long-term debt0000
Deferred revenue and credits0   
Other liabilities0000
Total noncurrent liabilities:0037
Total liabilities:251015
Temporary equity, carrying amount3   
Stockholders' equity
Stockholders' equity attributable to parent(2)1(1)0
Common stock0000
Additional paid in capital164162152137
Accumulated deficit(166)(161)(153)(137)
Total stockholders' equity:(2)1(1)0
TOTAL LIABILITIES AND EQUITY:25915

Income statement (P&L) ($ in millions)

12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
2343
Cost of revenue
(Cost of Goods and Services Sold)
(1)(1)(1)(1)
Gross profit:1232
Operating expenses(6)(9)(17)(25)
Other undisclosed operating income 00 
Operating loss:(5)(7)(14)(23)
Nonoperating income (expense)(1)000
Investment income, nonoperating 000
Other nonoperating income (expense)(1)000
Interest and debt expense(0)(1)(1)(1)
Net loss:(5)(8)(16)(24)
Other undisclosed net loss attributable to parent  (0) 
Net loss attributable to parent:(5)(8)(16)(24)
Preferred stock dividends and other adjustments(2)   
Net loss available to common stockholders, diluted:(7)(8)(16)(24)

Comprehensive Income ($ in millions)

12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss:(5)(8)(16)(24)
Comprehensive loss, net of tax, attributable to parent:(5)(8)(16)(24)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: